Definitive Contract 75F40123C00074

Award Date 9/13/23
Potential Completion Date 12/9/28
Potential Value $1M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Menlo Park, CA 94025, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration awarded a Firm Fixed Price Purchase Order contract to Pacific Biosciences of California, Inc., a small business manufacturer, for the delivery of PacBio Revio sequencing reagent kits or equal products. The $48,715.20 contract has a completion date of September 30, 2024 and will support research at the FDA's National Center for Toxicological Research. This award is associated with a larger $1 million single-award Indefinite Delivery Indefinite Quantity (IDIQ)...
This firm-fixed-price purchase order was awarded to Pacific Biosciences of California, Inc. (PacBio), a leading manufacturer of high-throughput DNA sequencing systems and related consumables, by the U.S. Food and Drug Administration (FDA). The $48,715.20 contract is for the delivery of PacBio's Revio Reagent Kit, part number 102-817-900, with a period of performance through September 9, 2024. PacBio holds two significant IDIQ contract vehicles with federal agencies - a $13.5 million IDIQ with...
The U.S. Food and Drug Administration (FDA) has awarded a $39,657.00 firm fixed-price delivery order to Pacific Biosciences of California, Inc. (PacBio) under the company's existing $1 million Indefinite Delivery, Indefinite Quantity (IDIQ) contract with the agency. This delivery order is for the purchase of specific supplies and reagents to support the agency's use of PacBio's Sequel IIe long-read DNA/RNA sequencing platform. The award, made without a set-aside designation, is the latest task...
This is a $46,512 firm-fixed price purchase order awarded by the U.S. Food and Drug Administration (FDA) to Pacific Biosciences of California, Inc., a small business manufacturer, for the delivery of reagents and consumables compatible with the FDA's PacBio Revio DNA/RNA sequencing instrument. The award is the result of a small business set-aside solicitation for these specialized sequencing supplies to support the FDA National Center for Toxicological Research's (NCTR) error-corrected...
This is a firm fixed-price definitive contract awarded by the Department of Health and Human Services' Food and Drug Administration to Pacific Biosciences of California, Inc., a small business manufacturer of specialized scientific equipment and consumables. The contract, valued at $736,000.00, is for the provision of Pacific Biosciences' Sequel and Sequel II real-time DNA/RNA sequencing systems, along with associated reagent kits, adapters, and software to support the FDA's genomic research...
This federal contract award is for the procurement of PacBio Sequel II and IIe system reagents and consumables by the Food and Drug Administration (FDA). The $15,713.10 firm-fixed price contract was awarded on July 23, 2024 to Pacific Biosciences of California, Inc., a leading manufacturer of high-throughput, long-read DNA sequencing platforms and associated products. The contract does not have a set-aside designation. Pacific Biosciences holds two relevant Indefinite Delivery Indefinite...
This federal contract award to Pacific Biosciences of California, Inc. (PacBio) provides for the delivery of a PacBio RS DNA sequencing system with a 12-month service contract. The $998,000.00 firm fixed price contract was awarded by the Food and Drug Administration (FDA), a civilian agency, without the use of a set-aside. PacBio is the original equipment manufacturer for the PacBio Sequel and Sequel II sequencing platforms, which are in high demand across federal agencies for genomic research...
This is a firm-fixed price purchase order awarded by the Food and Drug Administration (FDA) to Pacific Biosciences of California, Inc. for $24,357.60 to provide PacBio reagents. The contract has a completion date of September 30, 2024 and does not have a set-aside designation. Pacific Biosciences is the original equipment manufacturer of the Sequel and Sequel II DNA/RNA sequencing platforms, which are used by federal agencies like the FDA, CDC, USDA, and NIH to support genomic research across...
This $274,176 firm-fixed price purchase order was awarded by the National Human Genome Research Institute, a civilian agency within the Department of Health and Human Services, to Pacific Biosciences of California, Inc., a for-profit manufacturer. The contract is for the delivery of PacBio Revio sequencing reagents, which support the agency's genomic research initiatives. Pacific Biosciences is the original equipment manufacturer for the proprietary PacBio Sequel and Sequel II DNA/RNA sequencing...
This contract award to Pacific Biosciences of California, Inc., a small business manufacturer, is for the provision of high-throughput, long-read DNA sequencing systems and associated consumables to the U.S. Food and Drug Administration (FDA). The $83,644 firm fixed-price purchase order has an ultimate completion date of October 14, 2015. Pacific Biosciences is the original equipment manufacturer for their proprietary single molecule, real-time (SMRT) sequencing technology, which is utilized...

The Food and Drug Administration (FDA) awarded a $1,000,000 firm-fixed price contract to Pacific Biosciences of California, Inc. for a PacBio Revio System. The Revio System will be used by the FDA's National Center for Toxicological Research to support its genetic and molecular toxicology research programs, particularly in the areas of mutation detection and sequencing. The contract has a period of performance through December 9, 2028 and includes a one-year warranty as well as four one-year post-warranty maintenance and repair option periods. This contract was not set aside for any specific business size or socioeconomic category. Pacific Biosciences specializes in high-throughput DNA and RNA sequencing technologies and has been awarded multiple contracts and indefinite delivery/indefinite quantity vehicles by federal agencies including the USDA, FDA, NIH, and CDC to provide advanced genomic research capabilities and services.

Generated 7/1/25, 9:11 AM